Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
85 studies found for:    "Berger disease"
Show Display Options
Rank Status Study
1 Not yet recruiting Efficacy and Safety of Atacicept in IgA Nephropathy
Condition: IgA Nephropathy
Interventions: Drug: atacicept 25 mg;   Drug: atacicept 75 mg;   Drug: atacicept 150 mg;   Drug: Placebo
2 Completed
Has Results
A Controlled Study of Uric Acid on the Progression of IgA Nephropathy
Condition: IgA Nephropathy
Interventions: Drug: allopurinol;   Other: continue their usual therapy
3 Completed An Observational Study of IgA Nephropathy: Pathological Variants and Clinical Data
Condition: IgA Nephropathy
Intervention:
4 Active, not recruiting Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)
Condition: IgA Nephropathy
Interventions: Drug: irbesartan;   Drug: methylprednisolone (MP) or prednisone (pred);   Drug: mycophenolate mofetil (MMF)
5 Completed A Survey of Factors Affecting an Early or Delayed Diagnosis of IgA Nephropathy
Condition: IgA Nephropathy
Intervention:
6 Recruiting Rituximab in Recurrent IgA Nephropathy
Condition: Recurrent IgA Nephropathy
Interventions: Drug: Intravenous Rituximab;   Drug: ACEI/ARB and corticosteroids
7 Active, not recruiting Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy
Condition: IgA Nephropathy
Interventions: Drug: prednisone plus cyclophosphamide;   Drug: Prednisone alone
8 Suspended Effect of Tonsillectomy on Longterm Renal Outcome of IgA Nephropathy
Condition: IgA Nephropathy
Interventions: Procedure: tonsillectomy;   Other: non-tonsillectomy
9 Active, not recruiting Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Study)
Condition: IgA Glomerulonephritis
Interventions: Drug: methylprednisolone;   Drug: Placebo
10 Not yet recruiting Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy
Condition: IGA Nephropathy
Interventions: Drug: Prednisolone;   Drug: Reh-acteoside
11 Not yet recruiting Integrative Medicine of IgA Nephropathy
Condition: Primary IgA Nephropathy
Interventions: Drug: WM (Shentong Granules);   Drug: Hormone (prednisone)
12 Completed Mycophenolate Mofetil Versus Intravenous Cyclophosphamide Pulses in the Treatment of Crescentic IgA Nephropathy
Condition: IGA Nephropathy
Intervention: Drug: Mycophenolate mofetil
13 Completed Role of Regulatory T Cells in Pathogenesis of Primary IgA Nephropathy
Condition: Glomerulonephritis, IGA
Intervention: Procedure: gene transcription and cytometry
14 Completed The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease
Condition: Primary IgA Nephropathy
Interventions: Drug: NEFECON;   Other: Placebo
15 Recruiting Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy
Condition: IgA Nephropathy
Interventions: Drug: Losartan;   Drug: Abelmoschus manihot
16 Withdrawn BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy
Condition: IgA Nephropathy
Interventions: Drug: Blisibimod;   Drug: Placebo
17 Completed IgA Nephropathy, Lymphocyte Homing and IgA Class Switch
Condition: IgA Nephropathy
Intervention: Other: blood test
18 Completed Mycophenolate Mofetil for IgA Nephropathy
Condition: IGA Nephropathy
Interventions: Drug: mycophenolate mofetil;   Drug: angiotensin blockade
19 Active, not recruiting BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration
Condition: IgA Nephropathy
Interventions: Drug: Blisibimod;   Drug: Placebo
20 Withdrawn Paricalcitol for the Treatment of Immunoglobulin A Nephropathy
Condition: IgA Nephropathy
Intervention: Drug: paricalcitol

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.